Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSoligenix expands ATM offering by $2.96M after selling $3.45M in shares
Filed May 28, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
medium
Company increased its at-the-market equity offering capacity by $2.956 million, allowing it to sell additional common shares gradually through broker Rodman & Renshaw as needed for capital.
Item 8.01 verify on EDGAR → -
medium
Soligenix previously sold approximately $3.445 million in shares under the original ATM agreement initiated in January 2026, indicating ongoing dilution to existing shareholders through equity issuance.
Item 8.01 verify on EDGAR → -
low
Filed routine legal opinion and consent from Duane Morris LLP related to the validity of securities being offered under the expanded ATM program.
Item 9.01 verify on EDGAR →
Summary
Soligenix expanded its at-the-market equity offering program by nearly $3 million, providing the biotech company additional capacity to raise capital by selling shares directly into the market. The filing reveals the company has already tapped its original ATM facility for approximately $3.45 million since January 2026, demonstrating active use of this financing mechanism.
Retail investors should understand that ATM offerings create ongoing dilution as new shares are issued, potentially pressuring the stock price. Unlike traditional offerings with set pricing, ATM programs allow companies to sell shares opportunistically over time. For a small biotech like Soligenix, this suggests the company needs continued capital infusions to fund operations.
Watch for the company's quarterly filings to see how quickly it uses this expanded capacity and what the proceeds fund. The pace of share issuance and resulting dilution will directly impact existing shareholders' ownership percentage and could signal the company's cash runway and financing needs.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 28, 2026, Soligenix, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement dated January 23, 2026 (the “Sales Agreement”) with Rodman & Renshaw LLC, by an additional aggregate amount of $2,956,000.
The company filed a prospectus supplement to expand its at-the-market (ATM) equity offering program by $2,956,000. This allows Soligenix to sell additional shares of common stock through its broker Rodman & Renshaw to raise capital as needed. ATM programs let companies sell shares gradually into the market rather than in a single large offering.
Added in current filing · verify on EDGAR →
The Company previously sold approximately $3,445,000 of shares of common stock pursuant to the Sales Agreement under a prior prospectus supplement.
The disclosure reveals that Soligenix has already raised approximately $3,445,000 by selling shares under the original ATM agreement. This provides context on the company's recent capital-raising activity and indicates ongoing dilution to existing shareholders through equity issuance.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
Exhibit No. | Description | 5.1 | Opinion of Duane Morris LLP | 23.1 | Consent of Duane Morris LLP
The company filed a legal opinion and consent from law firm Duane Morris LLP. These exhibits typically accompany securities registration statements and relate to the validity of securities being offered, but no underlying transaction or offering is described in this 8-K.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify